Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Alex Shimmings
Patent expiries, novel pipeline treatments, and more patients are set to shake up the gastrointestinal stromal tumor market, finds Datamonitor Healthcare.
The Roche affiliate doubles the potential monetary value of partnership focused on PROTAC technology in a range of therapeutic areas. Cardinal sells off Chinese business for $1.2bn, while Novartis licenses Homology’s gene-editing technology.
Novartis is taking its unexpected CANTOS cancer findings for canakinumab and running with them to Phase III in an adjuvant lung cancer setting that is broader that AstraZeneca's PACIFIC study.
New CANTOS analyses show that the "lower is better" mantra applies to inflammation as well as LDL-cholesterol. Novartis hopes they will lead canakinumab to becoming the first targeted anti-inflammatory therapy for heart attack patients, but hurdles lie ahead.
Expanded US approval for Alecensa in ALK-positive NSCLC will stand the product in good stead as it helps make up for upcoming biosimilar threat to Avastin, Rituxan and Herceptin.
AbbVie's investigational monoclonal antibody therapy risankizumab has triumphed against its competitors in three Phase III trials in psoriasis, but will it be too late to the party to enjoy the full commercial benefits?